Catalent Pharma Solutions has signed a multi-year agreement with Grid Therapeutics, LLC, for the development and manufacture of Grid’s lead therapeutic candidate for the treatment of solid tumors.   Catalent Biologics will employ its GPEx cell line technology to develop cell lines and manufacture antibodies with the goal of optimizing the process for cGMP bulk drug production. The project will be undertaken at Catalent’s Madison, WI, biomanufacturing facility.   Grid’s research is based on a...